One of our regular readers, Thomas from Germany, forwarded me this archived article from last year. He feels it is important because it “explains in a logic manner to me why myeloma cells could fight against so many agents successfully. If a cancer center develops a strategy against this “environmental myeloma supply chain.” I agree this is worth a look:
pDCs promote growth and survival of malignant myeloma cells
Multiple myeloma cancer cells thwart many of the drugs used against them by causing nearby cells to turn traitor – to switch from defending the body against disease to shielding the myeloma cells from harm – Dana-Farber Cancer Institute scientists report in the October issue of Cancer Cell.
The researchers found that immune-system cells known as plasmacytoid dendritic cells (pDCs) essentially assume a new identity in the presence of myeloma – promoting the growth and survival of malignant myeloma cells, helping them fend off drugs, and depleting the overall strength of the immune system. The discovery not only helps explain a little-understood aspect of myeloma biology, but also suggests a new angle of attack on the disease. Researchers found that compounds that alight on specific sites on pDCs restore the cells’ original disease-fighting character and remove a trigger of myeloma cell growth.
Access this article on News – Medical.net.
Thanks, Thomas! Feel good and keep smiling! Pat